NCT00919282View on ClinicalTrials.gov

Gemcitabine (GFF) in Patients With Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

September 30, 1997

Primary Completion Date

July 31, 2000

Study Completion Date

December 31, 2002

Conditions
Metastatic Pancreatic Cancer
Interventions
DRUG

gemcitabine, folinic acid, 5-FU

gemcitabine 1g/m² - 30 minutes folinic acid 500mg/m² - 2 hours 5-FU 750mg/m² - over 24hours

Trial Locations (1)

13353

Universitätsmedizin Berlin, Berlin

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

CONKO-Studiengruppe

OTHER

NCT00919282 - Gemcitabine (GFF) in Patients With Pancreatic Cancer | Biotech Hunter | Biotech Hunter